Micafungina Accord

Micafungin, the active ingredient in Micafungina Accord, is an echinocandin presented as an injectable solution for intravenous use. It treats invasive candidiasis, esophageal candidiasis, and is used for prophylaxis of Candida infections in hematopoietic stem cell transplantation as well as Candida peritonitis and intra‑abdominal infections.

GNH USA supplies Micafungina Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Micafungin is an echinocandin antifungal that inhibits fungal cell wall synthesis and is indicated for several serious Candida infections.

Invasive candidiasis: treatment of bloodstream and deep‑tissue Candida infections. Esophageal candidiasis: eradication of Candida infection of the esophagus. Prophylaxis in hematopoietic stem cell transplantation: prevention of Candida infection in transplant recipients. Candida peritonitis and intra‑abdominal infections: management of intra‑abdominal Candida infections.

Micafungin may cause a range of adverse reactions, most of which are related to infusion or hepatic metabolism.

Common Side Effects: - Infusion‑related reactions (flushing, chills, dyspnea) - Fever or rigors during or after infusion - Nausea or vomiting - Headache - Elevated liver enzymes (ALT, AST) - Rash or pruritus

Serious or Rare Side Effects: - Severe hepatic dysfunction or hepatitis - Anaphylactic or severe hypersensitivity reactions - Acute renal failure - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Severe neutropenia or thrombocytopenia - Unexplained hypotension or cardiovascular collapse

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor relevant laboratory parameters.

Renal impairment: adjust monitoring of renal function and fluid status. Hepatic impairment: monitor liver function tests regularly. Concomitant hepatotoxic drugs: avoid or use with caution due to additive liver risk. Pregnancy Category B: weigh potential benefits against unknown fetal risks. Known hypersensitivity: discontinue if allergic reaction occurs. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with several drug classes, requiring attention to dosing and monitoring.

Major Interactions (Avoid): - Rifampin: may markedly reduce micafungin exposure. - Cyclosporine: can increase micafungin plasma concentrations. - Co‑administration with other echinocandins: risk of additive toxicity.

Moderate Interactions (Monitor Closely): - Azole antifungals (fluconazole, voriconazole): potential additive hepatotoxicity. - Immunosuppressants (tacrolimus, sirolimus): monitor drug levels for possible changes. - Warfarin: monitor INR for altered anticoagulant effect.